We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+7.83%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.92B
AUM Growth
-$347M
Cap. Flow
-$415M
Cap. Flow %
-14.2%
Top 10 Hldgs %
63.83%
Holding
68
New
13
Increased
7
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$75.9M
2
VRDN icon
Viridian Therapeutics
VRDN
+$32M
3
MBX
MBX Biosciences
MBX
+$26.9M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$23.3M
5
RLAY icon
Relay Therapeutics
RLAY
+$18.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$222M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$170M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$153M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$30.5M
5
ITOS
iTeos Therapeutics
ITOS
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRGX
26
DELISTED
CARGO Therapeutics
CRGX
$27.1M 0.93%
1,470,000
– –
ADAP
27
DELISTED
Adaptimmune Therapeutics
ADAP
$26M 0.89%
27,404,070
– –
TECX
28
Tectonic Therapeutic
TECX
$578M
$25.7M 0.88%
849,143
– –
TCRX icon
29
TScan Therapeutics
TCRX
$50.2M
$24.9M 0.85%
5,000,000
– –
VYGR icon
30
Voyager Therapeutics
VYGR
$187M
$22.9M 0.78%
3,917,546
– –
CLDX icon
31
Celldex Therapeutics
CLDX
$2.8B
$22.1M 0.76%
650,000
– –
BCYC
32
Bicycle Therapeutics
BCYC
$276M
$20.6M 0.7%
910,000
– –
IONS icon
33
Ionis Pharmaceuticals
IONS
$9.25B
$20M 0.69%
+500,000
New +$23.3M
DYN icon
34
Dyne Therapeutics
DYN
$4.24B
$20M 0.68%
555,644
+128,605
+30% +$5.12M
AVIR icon
35
Atea Pharmaceuticals
AVIR
$386M
$18.2M 0.62%
5,441,896
– –
RLAY icon
36
Relay Therapeutics
RLAY
$4.06B
$17.7M 0.61%
+2,500,000
New +$18.7M
PHVS icon
37
Pharvaris
PHVS
$2.37B
$16.7M 0.57%
900,000
– –
ITOS
38
DELISTED
iTeos Therapeutics
ITOS
$16.4M 0.56%
1,608,616
-1,641,219
-51% -$25M
MDGL icon
39
Madrigal Pharmaceuticals
MDGL
$12.7B
$15.9M 0.54%
75,000
– –
DAWN
40
DELISTED
Day One Biopharmaceuticals
DAWN
$12M 0.41%
+862,068
New +$12.3M
KROS icon
41
Keros Therapeutics
KROS
$202M
$10.9M 0.37%
187,500
– –
REPL icon
42
Replimune Group
REPL
$724M
$9.32M 0.32%
850,341
– –
KLRS
43
Kalaris Therapeutics
KLRS
$85.2M
$9.13M 0.31%
491,069
– –
LENZ
44
LENZ Therapeutics
LENZ
$179M
$8.23M 0.28%
346,772
-873,002
-72% -$19.4M
VERV
45
DELISTED
Verve Therapeutics
VERV
$6.05M 0.21%
1,250,000
– –
GBIO
46
DELISTED
Generation Bio
GBIO
$5.06M 0.17%
204,687
– –
LKFT
47
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$4.46M 0.15%
155,006
-5,601,262
-97% -$153M
BBIO icon
48
BridgeBio Pharma
BBIO
$16.5B
$4.33M 0.15%
+170,172
New +$4.47M
ATRA icon
49
Atara Biotherapeutics
ATRA
$69.5M
$3.81M 0.13%
468,938
+62,259
+15% +$533K
WHWK
50
Whitehawk Therapeutics
WHWK
$183M
$3.8M 0.13%
+1,845,253
New +$2.98M
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2024 Portfolio in Review

As of Q3 2024, EcoR1 Capital held 68 positions worth $2.92B, down 11% from $3.27B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

EcoR1 Capital withdrew a net $415M in Q3 2024, closing 4 positions and reducing 7 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $222M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, EcoR1 Capital opened a new position in Viridian Therapeutics worth $44.6M.

  • EcoR1 Capital's largest Q3 2024 buy was Viridian Therapeutics: 1,958,847 shares worth $44.6M.
  • EcoR1 Capital added most to Jazz Pharmaceuticals in Q3 2024, an estimated $75.9M increase.
  • EcoR1 Capital's biggest Q3 2024 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $153M.
  • EcoR1 Capital fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $222M.
  • EcoR1 Capital's ten largest holdings make up 64% of its $2.92B portfolio in Q3 2024.
  • EcoR1 Capital opened 13 new positions and closed 4 in Q3 2024.
  • EcoR1 Capital's portfolio value fell 11% quarter-over-quarter to $2.92B.

Based on EcoR1 Capital's 13F filing for Q3 2024, filed 14 Nov 2024.